Special studies/analysis- chemical/biological
Ended Awarded Last action
- Contract number
- HHSN26100016
- Awardee
-
Societal Cdmo San Diego, LLC UEI YRPTVKHDL7Z5 Part of Irisys, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $82,758
Award facts
- Opportunity
-
- N02CM5700205 Solicitation number
- Manufacture of Oral and Topical Dosage Forms Award Notice · Posted Jul 6, 2015
- Manufacture of Oral and Topical Dosage Forms Award Notice · Posted Jan 6, 2015
- Contract value 100% obligated
- $82,758.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Original award | $82,758 |
About this award
This is a federal contract award to Societal CDMO San Diego, LLC, doing business as Irisys Inc., a self-certified small disadvantaged business and limited liability company. The $82,758 contract is a cost-plus-fixed-fee delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services (HHS).
The contract is for "Special Studies/Analysis - Chemical/Biological" work, which includes pharmaceutical product development, manufacturing, and testing services to support the NCI's clinical research and drug development efforts, particularly in the areas of oncology, neurology, addiction, and rare diseases. Societal CDMO San Diego has provided various drug formulations, including oral capsules, injectable solutions, and nasal sprays, for investigational new drugs and clinical trials. The company has produced compounds such as metarrestin, z-endoxifen, AZA-TDC, and TAK-243 for cancer research, and has also conducted stability studies, shelf-life assessments, and analytical testing.
This contract is part of Societal CDMO San Diego's broader work under multiple federal Indefinite Delivery Vehicle (IDV) contracts, including a $45 million Drug Formulation and Manufacturing Contracts 2019 multiple-award IDV with the NIH, and single-award IDVs with the Department of Veterans Affairs for the production and supply of imiquimod cream formulations for cancer prevention research.
Quick answers
Who was awarded contract HHSN26100016?
HHSN26100016 was awarded to Societal Cdmo San Diego, LLC by National Cancer Institute (National Institutes of Health) on January 30, 2017.
How much is contract HHSN26100016 worth?
The government has obligated $82,758 on HHSN26100016.
Is contract HHSN26100016 an order under another contract?
Yes. HHSN26100016 is a delivery order under HHSN261201500009I, an indefinite delivery contract.
Was contract HHSN26100016 competed?
The extent of competition for HHSN26100016 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award